<div id="readability-page-1"><article>Collaboration expands Owlet’s national DME footprint, strengthens access for Medicaid and TRICARE families, and supports continued growth in prescription-backed revenue channel. LEHI, Utah--(BUSINESS WIRE)--Owlet, Inc. (“Owlet” or the “Company”) (NYSE: OWLT), the pioneer of smart infant monitoring, today announced a new durable medical equipment (DME) partnership with 1 Natural Way, a leading national mom-and-baby-focused DME provider. Families nationwide can now access Owlet’s FDA-cleared prescription pulse oximeter, BabySat, through insurance-supported pathways on 1NaturalWay.com.<div id="bwbodyimg"><img src="https://imageproxy.pbkrs.com/https://mms.businesswire.com/media/20251218723045/en/2673755/4/BabySat-1_%281%29.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://mms.businesswire.com/media/20251218723045/en/2673755/4/BabySat-1_%281%29.jpg"/>Families nationwide can now access Owlet’s FDA-cleared prescription pulse oximeter, BabySat, through insurance-supported pathways on 1NaturalWay.com.</div>Expanding Owlet’s DME Reach for Families Who Need It Most1 Natural Way offers a national, digital-first insurance fulfillment experience for moms and babies, working with major commercial plans, many state Medicaid networks, and TRICARE, the healthcare program for uniformed service members, retirees, and their family members. Together, Owlet and 1 Natural Way aim to reach more families who could benefit from clinically validated, prescription-supported home monitoring.“We are thrilled to expand the availability of Owlet products via 1 Natural Way, as a leader in the parenting space for essential products, specifically for mothers and babies,” said Jonathan Harris, Owlet’s President and CEO. “With a large online patient presence and many satisfied families, this partnership supports efficient digital acquisition and fulfillment for prescription BabySat.”By leveraging 1 Natural Way’s established relationships and national insurance infrastructure, Owlet aims to expand BabySat access for families with higher-risk infant health needs. This includes a focus on TRICARE families, representing roughly 9.5 million individuals across the Military Health System.“1 Natural Way was founded to bring compassion back into maternal care, a system that can too often feel impersonal and fragmented. Every mom deserves support that meets her where she is,” said Ryan Wright, CEO of 1 Natural Way. “Our partnership with Owlet continues our mission of ensuring that moms receive access to the highest level of care for themselves and their babies during a sensitive and deeply personal time in their lives.”How Families Access Owlet Through 1 Natural WayInterested families can visit 1NaturalWay.com to complete a short qualification questionnaire. With a prescription, caregivers can order BabySat through insurance-supported coverage where available. 1 Natural Way manages benefits verification and documentation support, reducing friction for both families and referring providers.To learn more or check coverage eligibility, visit 1naturalway.com/products/owlet-babysat. To learn more about Owlet’s pediatric monitoring devices, visit www.owletcare.com.For families who do not need prescription-level at-home infant monitoring, 1 Natural Way also offers the Company’s FDA-cleared Dream Sock® for added peace of mind. Insurance coverage and reimbursement for BabySat vary by plan and state and are not guaranteed. Eligibility is determined by individual payor policies and clinical requirements.About Owlet, Inc.Owlet, Inc. (NYSE: OWLT), a leading pediatric health platform, is the only company in the world to offer U.S. FDA-cleared and internationally medically-certified wearable pediatric monitors, delivering hospital-grade technology directly in the home. Our award-winning pediatric products and innovative software combine clinically tested monitoring systems, an integrated video platform, and a simple, easy-to-use app, providing parents with real-time health insights to stay informed on their child’s well-being, support restful sleep, and provide peace of mind anywhere. Since 2012, more than 2.5 million parents have trusted Owlet to monitor their children's well-being and sleep. This adoption has fueled one of the largest collections of pediatric health and sleep data in the world, powering innovations that bridge the critical gap between hospital and home. Owlet is driving a new standard in pediatric wellness by pairing advanced medical technology with consumer-friendly design. Our mission is simple yet ambitious: to give every baby and every family the best possible start in life. Learn more at www.owletcare.com and follow us on LinkedIn and Instagram for company news and updates.About 1 Natural WayFounded in 2014 and headquartered in Maumee, Ohio, 1 Natural Way is a trusted national medical equipment supplier delivering a digital-first insurance fulfillment experience for moms and babies across all 50 states, U.S. territories, and military bases overseas. The company provides a comprehensive portfolio of maternal health products, including FDA-cleared insurance-covered breast pumps, pregnancy support garments (compression socks, abdominal binders, lumbar support), blood pressure cuffs, breast pump parts, milk storage supplies, and the Owlet BabySat Infant Pulse Oximeter, along with nationwide access to maternal telehealth lactation services delivered by International Board Certified Lactation Consultants (IBCLCs) and maternity care specialists. Guided by a mission to make maternal care clearer, more compassionate, and easier to access, 1 Natural Way ensures families receive trusted products, expert support, and seamless insurance navigation during pregnancy and postpartum.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the Company’s expectations regarding the outcomes and benefits of Owlet’s partnership with 1 Natural Way; the Company’s ability to expand insurance-supported distribution channels, including through third-party DME partners; the availability, scope and continuity of reimbursement coverage under commercial plans, Medicaid, TRICARE and other government or private payor programs; and potential market reception and competitive positioning. In some cases, you can identify forward-looking statements by terms such as “estimate,” “may,” “believes,” “plans,” “expects,” “anticipates,” “intends,” “goal,” “potential,” “upcoming,” “outlook,” “guidance,” the negation thereof, or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on the Company’s expectations at the time such statements are made, speak only as of the dates they are made, and are susceptible to a number of risks, uncertainties, and other factors. For all such forward-looking statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. The Company’s actual results, performance or achievements may differ materially from any future results, performance or achievements expressed or implied by its forward-looking statements. Many important factors could affect the Company’s future results and cause those results to differ materially from those expressed in or implied by the Company’s forward-looking statements. Such factors include, but are not limited to, (i) the commercial success of BabySat, related software and services, and the 1 Natural Way integration; (ii) variability in insurance coverage, reimbursement rates, documentation requirements, clinical eligibility criteria, and payor determinations, including the risk that coverage may be reduced, delayed, denied or discontinued; (iii) the regulatory pathway for Owlet’s products, including submissions to, actions taken by and decisions and responses from regulators, such as the FDA and similar regulators outside of the United States, as well as Owlet’s ability to obtain and maintain regulatory approval or certification for its products and other regulatory requirements and legal proceedings; (iv) the Company’s and its partners’ obligations relating to data privacy, security and the exchange and use of health information (including HIPAA, HITECH and comparable laws, and evolving requirements governing such activities), and risks of cybersecurity incidents or changes in applicable standards or interpretations; (v) the performance of, and Owlet’s ability to maintain and expand, its relationship with 1 Natural Way and other third-party technology, cloud, manufacturing and distribution partners; (vi) Owlet’s competition and the Company’s ability to profitably grow and manage growth; (vii) the ability of Owlet to implement strategic initiatives, reduce costs, grow revenues, develop and launch new products, successfully execute and support integrations with third-party systems, innovate and enhance existing products, meet customer demands and adapt to changes in consumer and provider preferences and retail and healthcare trends; (viii) Owlet’s ability to acquire, defend and protect its intellectual property and satisfy regulatory requirements concerning privacy and data protection; (ix) Owlet’s ability to maintain relationships with healthcare providers and health systems, channel partners, customers, manufacturers and suppliers; (x) impacts from compliance with applicable laws or regulations; (xi) the impact of and disruption to Owlet’s business, financial condition, operations, supply chain and logistics due to economic and other conditions beyond the Company’s control; (xii) adverse impacts from other economic, business, regulatory, competitive or other factors, such as changes in discretionary consumer spending and consumer preferences, evolution of reimbursement and remote patient monitoring programs; and (xiii) Owlet’s reliance on a limited number of third-party DME, fulfillment and distribution partners for prescription-based revenue channels, and the risk that changes in those relationships could adversely affect access, reimbursement or revenue growth; (xiv) other risks and uncertainties set forth in the Company’s other releases, public statements and filings with the U.S. Securities and Exchange Commission (“SEC”), including those identified in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and as any such factors may be updated from time to time in the Company’s other filings with the SEC. All such forward-looking statements attributable to the Company or any person acting on the Company’s behalf are expressly qualified in their entirety by the cautionary statements contained or referred to above. Moreover, the Company operates in an evolving environment. New risk factors and uncertainties may emerge from time to time, and factors that the Company currently deems immaterial may become material, and it is impossible for the Company to predict such events or how they may affect Owlet. Except as required by law, the Company assumes no obligation to update any forward-looking statements after the date of this press release, whether because of new information, future events or otherwise, although Owlet may elect to do so from time to time. The Company does not endorse any projections regarding future performance that may be made by third parties.<img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTg3MjMwNDVyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTg3MjMwNDVyMQ"/>View source version on businesswire.com: https://www.businesswire.com/news/home/20251218723045/en/Media Contact: pr@owletcare.comInvestor Contact: ir@owletcare.com1 Natural Way Contact: mike.birney@1naturalway.comSource: Owlet, Inc.</article></div>

OWLT

Owlet, Inc. announced a new partnership with 1 Natural Way to expand access to its FDA-cleared BabySat infant pulse oximeter through insurance-supported pathways. This collaboration aims to strengthen access for Medicaid and TRICARE families and support growth in Owlet's prescription-backed revenue channel. Families can access BabySat via 1NaturalWay.com, which offers a digital-first insurance fulfillment experience. The partnership seeks to provide clinically validated home monitoring for higher-risk infants and enhance maternal care.

Owlet Announces New DME Partnership With 1 Natural Way to Expand Insurance-Supported Access to BabySat® Infant Pulse Oximeter | OWLT Stock News